A Meta-analysis of Therapeutic Effect of Thalidomide on Ankylosing Spondylitis

Authors

  • Yukun Yao Hebei University of Chinese Medicine
  • Xin Liu Hebei University of Chinese Medicine

DOI:

https://doi.org/10.30564/jams.v3i3.2271

Abstract

Objective: To study the therapeutic effect of thalidomide on ankylosing spondylitis (AS) by meta-analysis. Methods: Personal digital library, Cochrane library, and China Biology Medicine disc (CMBdisc), as well as relevant pharmaceutical and medical journals, were collected and reviewed. After the analysis of characteristics of the selected document and the evaluation of the risk of bias, the therapeutic effect of thalidomide on ankylosing spondylitis (AS) and its influence on related indexes were analyzed by literature data. Results: The meta-analysis results of 8 pieces of literature showed that the total effective rate of thalidomide in the treatment of ankylosing spondylitis (AS) was significantly improved, compared with conventional treatment or sulfasalazine (SASP) treatment (P＜0.05). Furthermore, the time of morning stiffness, BASDAI score, C-reactive protein (CRP) level, and other related symptoms and indexes were significantly optimized (P＜0.05). Conclusion: By rational utilization of thalidomide in the treatment of ankylosing spondylitis (AS), related symptoms and indexes of patients can be effectively improved, the total effective rate of the treatment was significantly improved and the safety of the treatment can be guaranteed.

Keywords:

Meta-analysis, Ankylosing spondylitis, Thalidomide, Clinical efficacy

References

[1] XIE DH. Discussion on the therapeutic effect of thalidomide on patients with ankylosing spondylitis[J]. The Medical Forum, 2020, 24(17):2405-2406.

[2] DOI: 10.19435/j.1672-1721.2020.17.021

[3] WANG Z, ZHAO XY, QUAN BT, HUANG GQ. Efficacy and safety of thalidomide in the treatment of ankylosing spondylitis[J]. Clinical Research and Practice, 2019(14):30-32.

[4] DOI:CNKI:SUN:YLYS.0.2019-14-012

[5] RAN J. Observation of therapeutic effect of thalidomide on ankylosing spondylitis[J]. Contemporary Medical Symposium, 2019 (01):137-138.

[6] DOI:10.3969/j.issn.2095-7629.2019.01.105

[7] HOU T. Analysis of the therapeutic effect of thalidomide on ankylosing spondylitis [J]. Henan Medical Research, 2018 (04):662-663.

[8] ZENG XL. Analysis of long-term efficacy and safety of thalidomide in the treatment of ankylosing spondylitis[J]. Journal of Qiqihar Medical College, 2017 (20):2412-2414.

[9] GUI YL, SHI LP, XUN W, LIU ZD, HAN D, LI TR. Observation of efficacy and safety of thalidomide in the treatment of ankylosing spondylitis[J]. Modern Diagnosis and Treatment, 2017 (18):3382-3384.

[10] DOI:10.3969/j.issn.1001-8174.2017.18.029

[11] LI GK, YUAN Y. Analysis of the efficacy of thalidomide on ankylosing spondylitis [J]. China Practical Medicine, 2016 (23):1-3.

[12] DOI: 10.14163/j.cnki.11-5547/r.2016.23.001

[13] LI YH, TAO LH, QIAN KW. Clinical efficacy of thalidomide on ankylosing spondylitis and its effect on the expression of inflammatory factors[J]. Shanxi Medical Journal, 2016 (03):247-249.

[14] DOI: 10.3969/j.issn.0253-9926.2016.03.002

Downloads

Issue

Vol. 3 , Iss. 3 (July 2020)

Article Type

Articles

License

Copyright and Licensing

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

Journal of Advances in Medicine Science publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Advances in Medicine Science agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.

License Policy for Reuse of Third-Party Materials

If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.

Journal Policies on Data Sharing

We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.